The neuroprotective mechanism of lithium after ischaemic stroke

Commun Biol. 2022 Feb 3;5(1):105. doi: 10.1038/s42003-022-03051-2.

Abstract

Stroke causes degeneration and death of neurones leading to the loss of motor function and frequent occurrence of cognitive impairment and depression. Lithium (Li+), the archetypal mood stabiliser, is neuroprotective in animal models of stroke, albeit underlying mechanisms remain unknown. We discover that Li+ inhibits activation of nucleotide-binding oligomerisation domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasomes in the middle cerebral artery occlusion (MCAO) stroke model in mice. This action of Li+ is mediated by two signalling pathways of AKT/GSK3β/β-catenin and AKT/FoxO3a/β-catenin which converge in suppressing the production of reactive oxygen species (ROS). Using immunocytochemstry, MRI imaging, and cell sorting with subsequent mRNA and protein quantification, we demonstrate that Li+ decreases the infarct volume, improves motor function, and alleviates associated cognitive and depressive impairments. In conclusion, this study reveals molecular mechanisms of Li+ neuroprotection during brain ischaemia, thus providing the theoretical background to extend clinical applications of Li+ for treatment of ischemic stroke.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cognitive Dysfunction / drug therapy
  • Depression / drug therapy
  • Gene Expression Regulation / drug effects
  • Ischemic Stroke / drug therapy*
  • Ischemic Stroke / pathology
  • Lithium / pharmacology*
  • Male
  • Mice
  • Mice, Transgenic
  • Neuroprotective Agents / pharmacology*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Random Allocation

Substances

  • Neuroprotective Agents
  • RNA, Messenger
  • Lithium